Wolverine (BPC-157 + TB-500 fragment)

What it is

Wolverine, in this catalog, is a lyophilized blend of BPC-157 and the TB-500 fragment (17–23). Component masses are selected on the sheet (5+5 or 10+10 mg). It does not contain full-length thymosin β-4.

What research explores

• Co-presentation of two reference peptides in one vial
• Preclinical models already linked to each component alone
• Identity and quantification assays for blends
• Analytical comparison versus single-component vials

Studies

There is no clinical evidence body specific to the “Wolverine” trade label. Applicable literature is that of each peptide; for TB-500, the fragment vs full-length distinction still applies. Human data for the combination are essentially absent.

Reported effects

Any literature effect must be traced to the component and model studied — not to the commercial blend. CodePept does not aggregate “synergy” claims.

In the literature

Published protocols typically address each peptide separately and are model-dependent. CodePept does not publish a combination protocol.

Specs

Format

Lyophilized powder

Quantity

5 mg + 5 mg / 10 mg + 10 mg

Store per the lot sheet, typically refrigerated and protected from light.

Lot: as stated by the manufacturer on the vial

Manufacturer COA — shown when the file exists in the data

Research use

Research use only (RUO). Not for human consumption.